

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT APPROVAL FOR ESTABLISHMENT OF NATIONAL AND LOCAL JOINT ENGINEERING LABORATORY

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group received a notice regarding the reply on year 2016 National and Local Joint Engineering Laboratory forwarded by Shijiazhuang Development and Reform Commission in December 2016. The quality control engineering laboratory for injections for chemical drugs (the “Laboratory”) established by the Group was renamed as the National and Local Joint Engineering Laboratory by National Development and Reform Commission.

The National and Local Joint Engineering Laboratory is a crucial integral part for national innovation system establishment. In accordance with national industry policies and the needs of strategic development, the Laboratory will perform researches on related theories and technology regarding quality control on the full production process of injections for chemical drugs. In addition, it will establish a base for evaluation on the quality consistency for injections and research & development for new products as well as develop high-tech talents, aiming at providing technical support for development of injections industry in China & ultimately become a pioneering laboratory for state-level research on injections for chemical drugs.

The establishment of the Laboratory will enhance the innovation capability of the Group, providing key technology and service for the development of the Group, which will in turn elevate the level of independence and innovation capability of injections for chemical drugs industry in China.

This announcement is a voluntary announcement made by the Company to keep the public investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 29 December 2016

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.